Nevertheless, while IDO may complement tolerogenic functions of BTLAhi cDC1s, recent results have also shown IDO activation in some mature cDC1s with high CCR7 expression, and not corresponding to BTLAhi cDC1s, that may promote the tolerogenic functionality in autoimmune models including non-obese diabetes (NOD) and EAE (Price et al., 2015; Tabansky et al., 2018; Gargaro et al., 2022). The gene discussed is IDO1; the disease is diabetes mellitus.